Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

@inproceedings{Wagner2013Anle138bAN,
  title={Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease},
  author={Jens Wagner and Sergey D. Ryazanov and Andrei Leonov and Johannes Levin and Song Shi and Felix Schmidt and Catharina Prix and Francisco J Pan-Montojo and Uwe Bertsch and Gerda Mitteregger-Kretzschmar and Markus Geissen and Martin Eiden and Fabienne Leidel and Thomas Hirschberger and Andreas A. Deeg and Julian J. Krauth and Wolfgang Zinth and Paul Tavan and Jens Pilger and Markus Zweckstetter and Tobias Frank and M. B{\"a}hr and Jochen H Weishaupt and M. Uhr and Henning Urlaub and Ulrike Teichmann and Matthias Samwer and Kai Boetzel and Martin H Groschup and Hans A. Kretzschmar and Christian Griesinger and Armin Giese},
  booktitle={Acta Neuropathologica},
  year={2013}
}
In neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and prion diseases, deposits of aggregated disease-specific proteins are found. Oligomeric aggregates are presumed to be the key neurotoxic agent. Here we describe the novel oligomer modulator anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole], an aggregation inhibitor we developed based on a systematic high-throughput screening campaign combined with medicinal chemistry optimization. In… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 68 references

Similar Papers

Loading similar papers…